News | March 19, 2026
Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students
SPARK has extended its influence to an additional 9.47 million students worldwide
SPARK has extended its influence to an additional 9.47 million students worldwide
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The company announced positive topline data from the Phase 3 ADorable-1 trial
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Subscribe To Our Newsletter & Stay Updated
